CD37

CD37 Informations sur la molécule

Nom anglais	Leukocyte antigen CD37	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	9	Alias de la cible	CD37，Tetraspanin-26，CD37 Molecule，CD37 Antigen，Tspan-26，TSPAN26，Cell Differentiation Antigen 37，Leukocyte Surface Antigen CD37，Leukocyte Antigen CD37，GP52-40
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Leukocyte antigen CD37
Alias de la cible	CD37，Tetraspanin-26，CD37 Molecule，CD37 Antigen，Tspan-26，TSPAN26，Cell Differentiation Antigen 37，Leukocyte Surface Antigen CD37，Leukocyte Antigen CD37，GP52-40
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	9
Phase de R&D la plus avancée	Phase 2 Clinical

CD37 Liste de produits

Attribut
Protein (5)
Bibliothèque de produits
En ligne (5)
Espèces
Human (5)
Étiquette
Fc Tag (2)His Tag (1)- (2)
Marqueur
Unconjugated (4)FITC Labeled (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT CD7-H52D3	Human	HEK293	Human CD37 Full Length Protein, His,Flag Tag (Detergent)	Ajouter au panier
HOT CD7-H52H3	Human	HEK293	Human CD37 Protein, His Tag	Ajouter au panier
HOT CD7-H52P4	Human	HEK293	Human CD37 Full Length Protein (VLP)	Ajouter au panier
CD7-H525a	Human	HEK293	Human CD37 Protein, Fc Tag (MALS verified)	Ajouter au panier
CD7-HF26x	Human	HEK293	FITC-Labeled Human CD37 Protein, Fc Tag	Ajouter au panier

Quantité totale5

CD37Contexte de la molécule

Leukocyte antigen CD37 (CD37) is also known as Tetraspanin-26 (Tspan-26) and TSPAN26,which is a member of the transmembrane 4 superfamily or tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins encoded by CD37 gene mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. CD37 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. CD37 may play a role in T-cell-B-cell interactions.

CD37Alias de la molécule

CD37,Tspan-26,TSPAN26

Coopération sous licence

Nom du projet	Type de médicament	Domain thérapeutique	Indication	Phase	Zone de droits
CD37+CD22 CAR-T	Cell therapy	Oncology/Cancer	AML	PCC	Global

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Lutetium (177lu) lilotomab satetraxetan	177Lu-DOTA-HH1	Phase 2 Clinical	Nordic Nanovector	Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin	Details
DS-3790a	DS3790a; DS-3790a	Phase 2 Clinical	Daiichi Sankyo Co Ltd	Hematologic Neoplasms	Details
Naratuximab emtansine	IMGN-529; K7153A-SMCC-DM1	Phase 2 Clinical	Immunogen Inc	Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin	Details
Debio-1562M	Debio-1562M	Phase 2 Clinical	Debiopharm International Sa	Leukemia, Myeloid, Acute; Neoplasms	Details
AGS-67E	AGS-67E	Phase 1 Clinical	Agensys Inc	Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin	Details
CAR-37 T cell therapy (Massachusetts General Hospital)		Phase 1 Clinical	Massachusetts General Hospital	Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell	Details
CAR-37 T cells(The General Hospital)		Phase 1 Clinical	The General Hospital Corporation D/B/A Massachusetts General Hospital	Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell	Details
anti-CD19 + anti-CD37 bispecific CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology)		Clinical	Huazhong University Of Science And Technology	Lymphoma, Non-Hodgkin	Details
DS3790	DS-3790; DS3790	Clinical	Daiichi Sankyo Inc	Hematologic Neoplasms	Details